|
Chief Executive Officer (CEO) of Sandoz Member of the Executive Committee of Novartis Andreas Rummelt is CEO of Sandoz, the generic pharmaceuticals division of Novartis, a position he assumed in November 2004.
He is responsible for the development and execution of the global strategy and for the operational management of Sandoz. He is also a member of the Executive Committee of Novartis. Following the acquisition of the generics companies Hexal in Germany and Eon Labs in the US in 2005, Andreas Rummelt led the integration of the combined companies. Prior to becoming CEO of Sandoz, he was Head of Global Technical Operations at Novartis Pharma AG from 1999 to 2004 and was a member of the Pharma Executive Committee. At Novartis Pharma AG, Andreas Rummelt was responsible for worldwide chemical, pharmaceutical, biotechnological and supply chain operations, as well as quality operations. In this position, he
drove the globalization of Technical Operations. Before leading Global Technical Operations, Andreas Rummelt was Head of Worldwide Technical Research & Development from 1994 to 1999 and was responsible for developing this function through the merger that created Novartis in 1996. From the time he joined Sandoz in 1985 through 1994, he served in various positions in Development, first as Laboratory Head, then as Group Head and finally as Department Head in Drug Delivery Systems. He obtained his Ph.D. in Pharmaceutical Sciences from the University of Erlangen-Nuremberg, Germany. He has received executive training in general management and leadership from IMD, INSEAD and Harvard Business School. | 